Keros Therapeutics, Inc. (KROS)

Stock NASDAQ

$10.03

+0.22 (+2.18%)

Delayed quote.

Price history

Daily close
KROS daily closing price, Nov 17, 2025 to Nov 16, 2026 Closed at $17.37 on Nov 17, 2025 and $10.03 on Nov 16, 2026, a change of -42.26%. Range $9.17 to $21.84.
Daily closes, Nov 17, 2025 to Nov 16, 2026 (251 trading days).
Start
$17.37
Latest close
$10.03
Period change
-42.26%
Period low
$9.17
Period high
$21.84

Key metrics

Market cap
$202.13M
Volume
167.0K
Average volume
191.1K
52-week range
$8.98 – $22.55
Beta
1.02
Last dividend
—
EPS (TTM)
-$2.81
P/E ratio
8.70
Revenue (TTM)
$40.76M
Net income (TTM)
-$61.73M
Total assets
$307.37M
Total debt
$15.11M
Cash and equivalents
$259.46M

Key financials (trailing twelve months).

Company profile

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
CEO
Jasbir S. Seehra
Employees
87
Headquarters
Lexington, MA, US
IPO date
2020-04-08

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Revenue$244.06M$3.55M$151.0K
Gross profit$242.55M$3.55M$151.0K
Operating income$70.62M-$210.83M-$169.94M
EBITDA$93.41M-$185.82M-$152.18M
Net income$87.01M-$187.35M-$152.99M
Diluted EPS$2.30-$5.00-$5.20
Balance sheet
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Cash and equivalents$287.42M$559.93M$331.15M
Total assets$338.02M$615.89M$370.02M
Total liabilities$34.89M$44.33M$37.81M
Total debt$16.88M$18.86M$14.44M
Shareholders’ equity$303.13M$571.55M$332.21M
Cash flow statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Operating cash flow$107.50M-$160.87M-$124.51M
Capital expenditure-$1.55M-$1.93M-$2.46M
Free cash flow$105.95M-$162.80M-$126.97M

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Revenue$40.01M$0$367.0K$385.0K$14.26M$18.17M
Gross profit$40.01M$0-$36.0K-$15.0K$13.87M$17.80M
Operating income$12.82M-$30.94M-$25.88M-$29.27M-$15.38M-$39.82M
EBITDA$14.93M-$28.31M-$23.30M-$24.57M-$8.31M-$32.55M
Net income$14.15M-$28.71M-$23.71M-$23.46M-$7.28M-$30.70M
Diluted EPS$0.70-$1.45-$1.21-$0.86-$0.18-$0.76
Balance sheet
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Cash and equivalents$259.46M$257.61M$281.50M$287.42M$693.47M$690.22M
Total assets$307.37M$287.60M$312.29M$338.02M$742.78M$757.16M
Total liabilities$28.27M$25.28M$26.66M$34.89M$39.20M$50.43M
Total debt$15.11M$15.72M$16.31M$16.88M$17.43M$17.95M
Shareholders’ equity$279.10M$262.32M$285.63M$303.13M$703.58M$706.73M
Cash flow statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Operating cash flow$3.39M-$20.42M-$3.53M-$27.29M$3.25M-$29.62M
Capital expenditure-$59.0K-$155.0K-$73.0K-$134.0K-$132.0K-$720.0K
Free cash flow$3.33M-$20.58M-$3.60M-$27.43M$3.12M-$30.34M